| Name | Title | Contact Details |
|---|
Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals™ is the backbone of the company`s Digital Therapeutics product pipeline, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.
ChipCare is a Toronto based start-up company developing a point of care blood testing platform for the global health market. The Company`s diagnostic platform is extremely mobile, simple to use, inexpensive and produces laboratory quality results. From single drops of blood, health workers in remote locations can rapidly and accurately perform tests to diagnose or monitor a range of infectious and non-communicable diseases.
Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.